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Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus (HBV). Even today, HBV infection
constitutes a global health problem, affecting more than 250 million people, and vaccination represents the most
cost-effective strategy to control HBV spreading. The main antigen of the HBV its the surface antigen (HBsAg),
that consists of three co-carboxyterminal envelope glycoproteins, called Large (L), Middle (M), and Small (S).
Current available HBV vaccines are based on the non-glycosylated form of the S protein, expressed in yeast
cells. Although efficacious and safe, about 10% of people vaccinated with this vaccine fail to mount an adequate
antibody response1. One approach to improve HBV vaccination response is increasing immunogenicity via the
inclusion of glycosylated S, M and L proteins in hepatitis B virus-like particles (HB-VLPs) expressed in
mammalian cells. This new generation vaccine has proven to be able to elicited higher antibody titers breaking
the lack of response to the current vaccine. On this regard, domains present in L and M proteins have shown to
be more immunostimulatory than the S protein2. Also, the L protein contains the hepatocyte receptor-binding
site and is able to induce the production of infection-neutralizing antibodies3.
In this work we generated stable CHO-K1 and HEK293 recombinant cells lines expressing the three HBV
envelope glycoproteins, as potential substrates for a production platform of a new generation vaccine for
hepatitis B. On the one hand, the coding sequence of S glycoprotein was cloned into third generation lentiviral
vectors and used to transduce CHO-K1 cells. Later, the cells were transfected with a plasmidic expression
vector carrying the coding sequences of M and L glycoproteins. On the other hand, HEK293 recombinant cells
were produced by transduction, using lentiviral vectors carrying the entire HBsAg sequence. The expression
level and subcellular localization of S glycoprotein (the main constituent of the HB-VLPs and the protein
necessary for the assemble and secretion of the subviral particles) were analyzed by flow cytometry and
confocal microscopy, respectively. Similar expression levels were observed between cell lines and the
cytoplasmic localization of the recombinant glycoprotein was determined. The budding of HB-VLPs to culture
supernatant of recombinant cells and the composition of the particles were evaluated by sandwich ELISA
assays. HB-VLPs were found to be secreted in both cell lines at a similar extent and it was possible to detect the
presence of the three envelope glycoproteins forming part of the particles. Identity and morphology of HB-VLPs
were analyzed by western blot and transmission electron microscopy (TEM), respectively. Western blot revealed
the presence of mainly the glycosylated form of S protein for particles produced in both cell types. Thus, as
expected, HB-VLPs were composed by the S protein as the major constituent, and M and L proteins as minor
components. Obtained images by TEM showed the presence of spherical particles with a diameter ranging from
20 to 28 nm for preparations of both cell types.
Further, immunogenicity of HB-VLPs was evaluated. For this, mice were inoculated intramusculary with HBVLPs derived from both cell lines. Other group of mice was injected with a preparation containing only the S
antigen, obtained from a commercially available vaccine, as control. HB-VLPs produced in both cell lines were
able to elicit specific antibodies against the S antigen, although no significant differences were observed in the
titers of antibodies triggered by HB-VLPs produced by HEK293 or CHO-K1 cells. Finally, we demonstrated that
the HB-VLPs produced in both cell types were able to induce the production of antibodies with specificity to the
region involved in the union of HBV to the hepatocyte, being higher the titer induced by HB-VLPs produced in
HEK-293 cell line. Therefore, these results encourage further studies to evaluate the neutralizing capacity of
these antibodies triggered by HB-VLPs, composed of the three envelope proteins of HBV, expressed in
mammalian cells.
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